Provided that it can be shown in animal models of atherosclerosis that Maxadilan has additive atheroprotective effects when combined with statins or PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, we suggest that therapeutic approaches with PAC1 agonists under real-world clinical conditions could complement clinical therapy with statins and and PCSK9 inhibitors of patients at risk of developing atherosclerosis-related pathologies. Here, PCSK9 is linked to atherosclerosis.